378 related articles for article (PubMed ID: 26663387)
1. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects.
Langenickel TH; Tsubouchi C; Ayalasomayajula S; Pal P; Valentin MA; Hinder M; Jhee S; Gevorkyan H; Rajman I
Br J Clin Pharmacol; 2016 May; 81(5):878-90. PubMed ID: 26663387
[TBL] [Abstract][Full Text] [Related]
2. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey.
Schoenfeld HA; West T; Verghese PB; Holubasch M; Shenoy N; Kagan D; Buono C; Zhou W; DeCristofaro M; Douville J; Goodrich GG; Mansfield K; Saravanan C; Cumin F; Webb RL; Bateman RJ
Toxicol Appl Pharmacol; 2017 May; 323():53-65. PubMed ID: 28315356
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I
Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595
[TBL] [Abstract][Full Text] [Related]
4. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor.
Gan L; Langenickel T; Petruck J; Kode K; Rajman I; Chandra P; Zhou W; Rebello S; Sunkara G
J Clin Pharmacol; 2016 Jan; 56(1):78-86. PubMed ID: 26073563
[TBL] [Abstract][Full Text] [Related]
5. Long-term neprilysin inhibition - implications for ARNIs.
Campbell DJ
Nat Rev Cardiol; 2017 Mar; 14(3):171-186. PubMed ID: 27974807
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.
Akahori M; Ayalasomayajula S; Langenickel T; Pal P; Zhou W; Sunkara G
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):407-416. PubMed ID: 27324506
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.
Han Y; Ayalasomayajula S; Pan W; Yang F; Yuan Y; Langenickel T; Hinder M; Kalluri S; Pal P; Sunkara G
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):109-116. PubMed ID: 26961539
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Gu J; Noe A; Chandra P; Al-Fayoumi S; Ligueros-Saylan M; Sarangapani R; Maahs S; Ksander G; Rigel DF; Jeng AY; Lin TH; Zheng W; Dole WP
J Clin Pharmacol; 2010 Apr; 50(4):401-14. PubMed ID: 19934029
[TBL] [Abstract][Full Text] [Related]
9. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
10. Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
.
Ayalasomayajula S; Langenickel TH; Chandra P; Wolfson ED; Albrecht D; Zhou W; Pal P; Rajman I; Sunkara G
Int J Clin Pharmacol Ther; 2016 Dec; 54(12):1012-1018. PubMed ID: 27719743
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects.
Ayalasomayajula S; Pan W; Han Y; Yang F; Langenickel T; Pal P; Zhou W; Yuan Y; Rajman I; Sunkara G
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):309-318. PubMed ID: 27245340
[TBL] [Abstract][Full Text] [Related]
12. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.
Langenickel TH; Jordaan P; Petruck J; Kode K; Pal P; Vaidya S; Chandra P; Rajman I
Eur J Clin Pharmacol; 2016 Aug; 72(8):917-24. PubMed ID: 27083930
[TBL] [Abstract][Full Text] [Related]
13. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.
Ayalasomayajula SP; Langenickel TH; Jordaan P; Zhou W; Chandra P; Albrecht D; Pal P; Rajman I; Sunkara G
Eur J Clin Pharmacol; 2016 Sep; 72(9):1065-73. PubMed ID: 27230850
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
Hsiao HL; Langenickel TH; Greeley M; Roberts J; Zhou W; Pal P; Rebello S; Rajman I; Sunkara G
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):407-17. PubMed ID: 27137712
[TBL] [Abstract][Full Text] [Related]
16. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
[TBL] [Abstract][Full Text] [Related]
17. The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.
Miura SI; Suematsu Y; Matsuo Y; Tomita S; Nakayama A; Goto M; Arimura T; Kuwano T; Yahiro E; Saku K
Hypertens Res; 2016 Nov; 39(11):758-763. PubMed ID: 27334058
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
Kario K; Sun N; Chiang FT; Supasyndh O; Baek SH; Inubushi-Molessa A; Zhang Y; Gotou H; Lefkowitz M; Zhang J
Hypertension; 2014 Apr; 63(4):698-705. PubMed ID: 24446062
[TBL] [Abstract][Full Text] [Related]
19. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
[TBL] [Abstract][Full Text] [Related]
20. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
Suematsu Y; Miura S; Goto M; Matsuo Y; Arimura T; Kuwano T; Imaizumi S; Iwata A; Yahiro E; Saku K
Eur J Heart Fail; 2016 Apr; 18(4):386-93. PubMed ID: 26749570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
